852854-42-3

Usage

Uses

Used in Dye and Pigment Synthesis:
4-Chloro-3-ethoxyaniline is utilized as an intermediate in the synthesis of various dyes and pigments, contributing to the coloration and stability of these compounds in different applications.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, 4-Chloro-3-ethoxyaniline serves as a key intermediate for the production of certain medications, playing a crucial role in the development of new drugs and the improvement of existing ones.
Used in Agrichemical Industry:
4-Chloro-3-ethoxyaniline is also employed as a component in the formulation of agrichemicals, where it may contribute to the effectiveness of pesticides or other agricultural products, enhancing crop protection and yield.

Upstream product

• 6358-06-1 5-amino-2-chlorophenol 
• 75-03-6 ethyl iodide 
• 102236-22-6 1-chloro-2-ethoxy-4-nitrobenzene 

Relevant academic research and scientific papers

NTCP INHIBITORS

Provided are cyclosporin A analogues that are NTCP inhibitors and useful for treating HBV and/or HDV infection (s), hepatoprotection and amelioration of hypercholesterolemia, diabetes and inhibiting cancer.

Development of 2-thioxoquinazoline-4-one derivatives as dual and selective inhibitors of dynamin-related protein 1 (Drp1) and puromycin-sensitive aminopeptidase (PSA)

An established inhibitor ot dynamin-related protein 1 (Drp1), 3-(2,4-dichloro-5-methoxyphenyl)- 2- thioxoquinazoline-4-one (mdivi-1), was recently reported also to show potent puromycin-sensitive aminopeptidase (PSA)-inhibitory activity. Herein, we report structural development of mdivi-1 derivatives and structure-activity relationship (SAR) analysis of the synthesized compounds, as well as the structurally related PSA-specific inhibitor 3-(2,6-diethylphenyl)quinazoline-2,4-dione (PAQ-22), with the aim of identifying key structural features for inhibitory activity in order to develop selective inhibitors of Drpl, which is a potential target for treatment of Huntington's disease. Among the synthesized compounds, 3-(4-chloro3methoxyphenyl)-2-thioxoquinazoline-4-one 10g) exhibited more potent Drpl-inhibitory activity than mdivi-1 with high selectivity for Drpl over PSA.

BICYCLIC PYRIMIDIN-4-(3H)-ONES AND ANALOGUES AND DERIVATIVES THEREOF WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1)

Compounds of formula (I); which are useful as therapeutic compounds, particularly in the treatment of pain and other conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1).